CohBar

CohBar, Inc. is a leader in the research and development of Mitochondrial-Based Therapeutics (MBT), a new class of drugs with the potential to treat various diseases associated with aging and metabolic dysfunction, including non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes (T2D), cancer, cardiovascular diseases, and central nervous system disorders. CohBar focuses on previously untapped areas of biology.